Remarkably, clinically feasible nano-delivery of PDLIM2 (nanoPDLIM2) shows a promising efficacy as a monotherapy, and in combination with ICIs and chemo drugs, completely eradicates all tumors in most animals without adding toxicity, in the preclinical model of refractory lung cancer (21, 31). Here, PDLIM2 is linked to lung cancer.